BRIEF published on 11/06/2024 at 09:48, 15 days 3 hours ago Crossing of thresholds by Invus Public Equities in GENEURO SA Euronext Paris Capital Increase Crossing Thresholds GeNeuro SA Invus Public Equities
BRIEF published on 11/06/2024 at 09:48, 15 days 3 hours ago Franchissement de seuils par Invus Public Equities dans GENEURO SA Euronext Paris Augmentation De Capital Franchissement De Seuils GeNeuro SA Invus Public Equities
PRESS RELEASE published on 11/06/2024 at 09:43, 15 days 3 hours ago Franchissement de seuils Déclaration de franchissement de seuils par Invus Public Equities, LP. concernant GENEURO SA sur Euronext Paris Euronext Paris Déclaration Franchissement De Seuils GeNeuro SA Invus Public Equities
BRIEF published on 06/28/2024 at 07:05, 4 months 23 days ago GeNeuro announces the results of the GNC-501 trial in post-Covid-19 syndrome Business Strategy Clinical Test GeNeuro Temelimab Post-Covid-19 Syndrome
BRIEF published on 06/28/2024 at 07:05, 4 months 23 days ago GeNeuro annonce les résultats de l’essai GNC-501 dans le syndrome post-Covid-19 Stratégie D'entreprise Essai Clinique GeNeuro Temelimab Syndrome Post-Covid-19
PRESS RELEASE published on 06/28/2024 at 07:00, 4 months 23 days ago Inside Information / Other news releases GeNeuro announces results of the GNC-501 study addressing post-COVID-19 neuropsychiatric syndromes. Initial findings show no significant improvement with temelimab treatment compared to placebo GeNeuro Temelimab Neuropsychiatric Post-Covid-19 Syndrome GNC-501 Study
PRESS RELEASE published on 06/28/2024 at 07:00, 4 months 23 days ago Informations privilégiées / Autres communiqués GeNeuro annonce les résultats de l’essai GNC-501 dans le syndrome post-Covid-19. Analyse des effets du temelimab chez des patients post-COVID-19. Réduction des coûts et effectifs chez GeNeuro GeNeuro Temelimab Syndrome Post-Covid-19 GNC-501 Réduction Coûts
BRIEF published on 06/14/2024 at 18:35, 5 months 6 days ago GeNeuro annonce l'approbation unanime des résolutions lors de l'AGA Actionnaires Biopharmaceutique Resolutions AGA GeNeuro
BRIEF published on 06/14/2024 at 18:35, 5 months 6 days ago GeNeuro Announces Unanimous Approval of Resolutions at AGM Shareholders Biopharmaceutical AGM Resolutions GeNeuro
PRESS RELEASE published on 06/14/2024 at 18:30, 5 months 6 days ago Inside Information / Other news releases GeNeuro shareholders approve all resolutions proposed at 2024 AGM, including annual report, re-election of Board members, and compensation approval. 81.54% share capital represented at the meeting Shareholders Compensation AGM Resolutions GeNeuro
Published on 11/21/2024 at 12:00, 1 hour 1 minute ago Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 1 hour 1 minute ago Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 31 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 58 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 3 hours 1 minute ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 12:35, 26 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 46 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 31 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 06:58, 6 hours 3 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 3 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 3 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 54 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 41 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
